A Novel Somatostatin-Dopamine Chimera (BIM23B065) Reduced GH Secretion in a First-in-Human Clinical Trial

A somatostatin-dopamine chimera (BIM23B065) was under investigation to reduce GH secretion for the treatment of pituitary adenomas. To determine pharmacokinetics, safety, and tolerability and to monitor hormonal changes after single and multiple subcutaneous BIM23B065 administrations. Randomized, do...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The journal of clinical endocrinology and metabolism 2019-03, Vol.104 (3), p.883-891
Hauptverfasser:	de Boon, Wadim M I, van Esdonk, Michiel J, Stuurman, Frederik E, Biermasz, Nienke R, Pons, Laurent, Paty, Isabelle, Burggraaf, Jacobus
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Cabergoline Clinical trials Dopamine Dopamine - administration & dosage Dopamine - adverse effects Dopamine - analogs & derivatives Dopamine - pharmacokinetics Dosage Dose-Response Relationship, Drug Double-Blind Method Growth hormone-releasing hormone Growth hormones Healthy Volunteers Hormone Antagonists - administration & dosage Hormone Antagonists - adverse effects Hormone Antagonists - pharmacokinetics Human Growth Hormone - antagonists & inhibitors Human Growth Hormone - blood Human Growth Hormone - metabolism Humans Hypotension Hypothalamus Injections, Subcutaneous Insulin-like growth factor I Insulin-Like Growth Factor I - analysis Male Middle Aged Pharmacokinetics Phenols Pituitary Pituitary Gland - drug effects Pituitary Gland - metabolism Pituitary Neoplasms - drug therapy Prolactin Prolactin - blood Safety Secretion Somatostatin Somatostatin - administration & dosage Somatostatin - adverse effects Somatostatin - analogs & derivatives Somatostatin - pharmacokinetics Somatotropin releasing hormone Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!